Precigen Inc
NASDAQ:PGEN
Intrinsic Value
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. [ Read More ]
The intrinsic value of one PGEN stock under the Base Case scenario is 9.14 USD. Compared to the current market price of 1.4 USD, Precigen Inc is Undervalued by 85%.
Valuation Backtest
Precigen Inc
Run backtest to discover the historical profit from buying and selling PGEN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Precigen Inc
Current Assets | 68.8m |
Cash & Short-Term Investments | 62.9m |
Receivables | 1.6m |
Other Current Assets | 4.3m |
Non-Current Assets | 82.3m |
PP&E | 14.2m |
Intangibles | 67.3m |
Other Non-Current Assets | 767k |
Current Liabilities | 23m |
Accounts Payable | 1.7m |
Accrued Liabilities | 20.8m |
Other Current Liabilities | 509k |
Non-Current Liabilities | 9.6m |
Other Non-Current Liabilities | 9.6m |
Earnings Waterfall
Precigen Inc
Revenue
|
6.2m
USD
|
Cost of Revenue
|
-6.1m
USD
|
Gross Profit
|
106k
USD
|
Operating Expenses
|
-89m
USD
|
Operating Income
|
-88.9m
USD
|
Other Expenses
|
-7m
USD
|
Net Income
|
-95.9m
USD
|
Free Cash Flow Analysis
Precigen Inc
What is Free Cash Flow?
PGEN Profitability Score
Profitability Due Diligence
Precigen Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
Score
Precigen Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
PGEN Solvency Score
Solvency Due Diligence
Precigen Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Score
Precigen Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PGEN Price Targets Summary
Precigen Inc
Ownership
PGEN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
PGEN Price
Precigen Inc
Average Annual Return | -1.09% |
Standard Deviation of Annual Returns | 74.43% |
Max Drawdown | -92% |
Market Capitalization | 348.5m USD |
Shares Outstanding | 248 919 008 |
Percentage of Shares Shorted | 11.44% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The company is headquartered in Germantown, Maryland and currently employs 456 full-time employees. The company went IPO on 2013-08-08. Its therapeutic platforms, including UltraCAR-T, AdenoVerse immunotherapy, and ActoBiotics, are designed to precisely control the level and physiological location of gene expression and modify biological molecules to control the function and output of living cells to treat underlying disease conditions. The Company’s lead clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on its UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on its AdenoVerse immunotherapy platform; and AG019, which is built on its ActoBiotics platform. The firm also completed a Phase I study of INXN-4001, a non-viral triple-effector plasmid DNA, which is built on its UltraVector platform. The company also has a robust pipeline of preclinical programs.
Contact
IPO
Employees
Officers
The intrinsic value of one PGEN stock under the Base Case scenario is 9.14 USD.
Compared to the current market price of 1.4 USD, Precigen Inc is Undervalued by 85%.